E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 diabetes and Heart Failure |
|
E.1.1.1 | Medical condition in easily understood language |
Diabetes and heart failure |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective will be to see if Dapagliflozin can change the harmful effect of scarring in the left ventricle in the heart of type 2 diabetic patients who have mild heart failure.
This will be done by measuring the size of the left side of the heart muscle with an MRI scan before and after one years of treatment with dapagliflozin or placebo. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to assess the effect of Dapagliflozin on the size of and pumping ability of the heart and to see if dapaliflozin improves exercise ability and if it improves fluid retention or if there is a reduction in water tablet (diuretic) use.
Additionally participants Quality of Life measures will be collected before and after treatment to examine if improvements or deterioration in their condition are reflected in how they feel and manage on a day to day basis.
As this is a novel use of dapagliflizon in diabetes associated with heart failure, it is important also to check it is safe to use it so information on adverse events and changes in blood markers will be collected.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• are aged 18 years or over • were previously diagnosed with Type 2 Diabetes • are diagnosed with NYHA functional I-II Heart Failure (HF) with prior echocardiographic evidence of LVSD • on furosemide 40mg daily or less, or equivalent loop diuretic • have stable HF symptoms for at least three months prior to consent • on stable therapy for HF for at least three months prior to consent • have not been hospitalised for HF for at least three months prior to consent
|
|
E.4 | Principal exclusion criteria |
• severe hepatic disease • renal disease defined as CKD class 3B or worse (i.e. eGFR<60ml/min) • systolic BP <95mmHg at screening visit • screening HbA1c <6.0% • unable to walk to perform cardio pulmonary exercise testing or 6MWT • on insulin, meglitinides eg, repaglinide, or 2nd generation sulphonylureas, eg glipizide • malignancy (receiving active treatment) or other life threatening diseases • pregnant or lactating women • any contraindication to MRI (e.g. claustrophobia, metal implants, penetrative eye injury or exposure to metal fragments in eye requiring medical attention) • patients who have participated in any other clinical trial of an investigational medicinal product within the previous 30 days • patients who are unable to give informed consent • any other reason considered by a study physician to be inappropriate for inclusion.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective will be to assess if dapagliflozin can alter LV remodelling in type 2 diabetic patients with mild HF-LVSD (as measured by MRI). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline- 0 weeks Endpoint- 12 months |
|
E.5.2 | Secondary end point(s) |
1) To determine if there is a change in LVESV, LVEDV, RVEDV, RVESV, RVEF, ventricular dimensions and left atrial volume with Dapagliflozin in DM associated HF compared with placebo. 2) To determine if there is a change in bioelectrical impedance analysis as a measure of fluid status with Dapagliflozin in DM associated HF compared with placebo 3) To determine of Dapagliflozin can improve exercise tolerance in DM patients with CHF pre and post six minute walk test and CPET compared to placebo. 4) To determine if there are patient reported improvements in quality of life with Dapagliflozin compared to placebo as measured by the Minnesota Living with Heart Failure Questionnaire and SF-36 questionnaire 5) To determine the effect of Dapagliflozin on BNP and inflammatory or other blood markers in DM associated CHF. 6) To assess the safety of Dapagliflozin in DM associated HF. 7) To assess if there are increased or decreased use of diuretics in DM associated HF with Dapagliflozin compared to placebo.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline- 0 weeks Endpoint- 12 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |